Relation Between Ambulatory Electrocardiographic Monitoring and Myocardial Perfusion Imaging to Detect Coronary Artery Disease and Myocardial Ischemia: An ACIP Ancillary Studyfn1fn1Support for electro cardiographic data collection was provided in part by Applied Cardiac Systems, Laguna Hills, California; Marquette Electronics, Milwaukee, Wisconsin; Mortara Instrument, Milwaukee, Wisconsin; and Quinton Instruments, Seattle, Washington. Some centers had partial support from General Clinical Research Center grants.  by Mahmarian, John J. et al.
Relation Between Ambulatory Electrocardiographic Monitoring and
Myocardial Perfusion Imaging to Detect Coronary Artery Disease and
Myocardial Ischemia: An ACIP Ancillary Study
JOHN J. MAHMARIAN, MD, FACC, RICHARD M. STEINGART, MD, FACC,* SANDRA FORMAN,†
BARRY L. SHARAF, MD, FACC,‡ MARY ELLEN COGLIANESE,* D. DOUGLAS MILLER, MD, FACC,§
CARL J. PEPINE, MD, FACC,\ A. DAVID GOLDBERG, MD, FACC,¶ MARILYN F. BLOOM, RN,
SHEILA BYERS,§ LAUREL DVORAK,¶ CRAIG M. PRATT, MD, FACC, FOR THE ASYMPTOMATIC
CARDIAC ISCHEMIA PILOT (ACIP) INVESTIGATORS#
Houston, Texas; Stony Brook, New York; Baltimore, Maryland; Providence, Rhode Island; Saint Louis, Missouri; Gainesville,
Florida; and Detroit, Michigan
Objectives. This study sought to explore the relation between
markers of ischemia detected by ambulatory electrocardiographic
(AECG) monitoring and stress myocardial perfusion single-
photon emission computed tomography (SPECT).
Background. Stress myocardial SPECT and AECG monitoring
are both utilized in evaluating patients with coronary artery disease.
However, information is limited regarding the relation between the
presence and extent of ischemia as detected by these two modalities.
Methods. This was an ancillary study of the Asymptomatic
Cardiac Ischemia Pilot (ACIP) trial. One hundred six patients
with previous coronary angiography underwent AECG monitoring
and stress SPECT within a close temporal time period. The
frequency and duration of ischemia as assessed by AECG moni-
toring and the total and ischemic stress-induced myocardial
perfusion defect sizes as assessed by SPECT were quantified in
separate core laboratories. Multivariate logistic regression and
linear regression analysis were used to determine associations
between AECG and SPECT abnormalities with regard to angio-
graphic, demographic and treadmill exercise variables.
Results. Seventy-four percent of patients with significant (>250%)
coronary artery stenosis had SPECT abnormalities, whereas 61%
had ischemia by AECG monitoring. The most important predictors
of SPECT abnormalities were severity (p < 0.001) of coronary artery
stenosis, followed by total exercise duration (p 5 0.016) and patient
age (p 5 0.04). The only predictor of AECG abnormalities was the
presence of ST segment depression on the initial exercise treadmill
test (p 5 0.021). Only a 50% concordance for normalcy or abnor-
malcy was observed between the SPECT and AECG results, and no
relation was observed between the frequency or duration of AECG
ischemia and the quantified total or ischemic myocardial perfusion
defect size as assessed by SPECT.
Conclusions. Ischemia as detected by AECG monitoring does
not correlate with the presence and extent of ischemia as quanti-
fied by stress SPECT. Because these techniques appear to detect
different pathophysiologic manifestations of ischemia, they may
be complementary in more fully defining the functional signifi-
cance of coronary artery disease and, in particular, which patients
are at highest risk for adverse cardiac events.
(J Am Coll Cardiol 1997;29:764–9)
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Myocardial perfusion scintigraphy is useful for both diagnosis
(1–12) and risk stratification (13–26) of patients with coronary
artery disease. Ambulatory electrocardiographic (AECG)
monitoring has also been extensively studied, particularly with
regard to its role in detecting myocardial ischemia during daily
life and in assessing prognosis (27–36). Although both tech-
niques have been utilized in patients with coronary artery
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disease, information evaluating the relation between the pres-
ence and extent of ischemia, as detected by these two modal-
ities, is limited.
The Asymptomatic Cardiac Ischemia Pilot (ACIP) study
(37) was a National Institutes of Health-sponsored trial de-
signed to assess the feasibility of conducting a major trial of
different treatment strategies for reducing myocardial isch-
emia. Patients were eligible for the ACIP trial if they had
documented coronary artery disease ($50% diameter steno-
sis) and electrocardiographic (ECG) evidence of ischemia on
both treadmill testing and 48-h AECGmonitoring. All patients
considered for the ACIP trial were evaluated with 48-h AECG
monitoring, and a subgroup also underwent stress myocardial
single-photon emission computed tomography (SPECT)
within a close temporal time period. In this regard, the ACIP
trial provided a unique opportunity to explore the relation
between markers of ischemia detected by AECG monitoring
and stress SPECT.
Study design and patient cohort. The ACIP study design
has been previously discussed in detail elsewhere (37). The
present ancillary study identified 160 patients, from 5 of the 10
sites, who underwent both AECG monitoring and SPECT
(Fig. 1). Of these 160 patients, 106 also underwent coronary
angiography and constitute the cohort for this ancillary study
(82 men, 24 women; mean [6SD] age 60 6 8 years, range 37
to 81).
Fifty patients were enrolled in the ACIP trial, and the
remaining 56 patients were excluded for various reasons
(Table 1). Four patients were excluded from the ACIP trial by
the local centers for having only insignificant (,50%) coronary
stenosis, but three of these patients were subsequently re-
ported by the angiographic core laboratory to have significant
single-vessel coronary artery disease. The majority of patients
(68%) had a history of angina within 6 weeks of AECG
monitoring. Myocardial SPECT was performed a mean of
466 72 days of AECG monitoring, and most patients (n5 79)
had perfusion imaging as the first test. SPECT was combined
with either treadmill exercise (n 5 92) or pharmacologic stress
(n 5 14).
Ambulatory electrocardiographic monitoring. AECG
monitoring consisted of two 24-h recordings using two-channel
cassette devices. Leads monitored were those demonstrating
greatest ST segment depression during baseline exercise test-
ing if an exercise test was done. Ischemic ST segment depression
was defined as reversible horizontal or downsloping ST seg-
ment depression $1 mm below the isoelectric line and $1 mm
below the baseline ST segment value or ST segment elevation
$1 mm above the isoelectric line and $1 mm above the
baseline ST segment value. An ischemic episode was defined as
ST segment deviation lasting $1 min. The AECG tapes were
analyzed in blinded manner with regard to clinical information
or treatment assignment by the core laboratory.
Coronary angiography. All coronary angiograms were ana-
lyzed in a core laboratory to determine the extent, location and
severity of coronary artery disease. Stenosis severity was semiquan-
titatively analyzed using electronic calipers. Significant coronary
artery disease was defined as$50% lumen diameter stenosis in at
least one of the three major coronary arteries. To be eligible for
the ACIP trial, coronary artery disease had to be documented on
an angiogram obtained within the past 3 years, unless the patient
had an interim clinical event for which a second angiogram was
required.
Single-photon emission computed tomography. SPECT
imaging was performed by the method previously reported
from our laboratory (2). At peak exercise or during pharma-
cologic stress, 3 mCi of thallium-201 (n 5 74) or 10 to 12 mCi
of technetium-99m sestamibi (n 5 32) was injected intrave-
nously and flushed with saline solution. Images were acquired
using a large field of view, single-crystal, rotating gamma
camera equipped with a high resolution, parallel-hole collima-
tor. Image acquisition was performed over an 1808 anterior arc
at 68 intervals and for 40 s/image.
SPECT images were quantified and displayed as polar maps
by one experienced investigator (J.J.M.) in the core laboratory
(2,26). The stress and 4-h delayed thallium-201 or rest
technetium-99m sestamibi images were independently com-
Abbreviations and Acronyms
ACIP 5 Asymptomatic Cardiac Ischemia Pilot
AECG 5 ambulatory electrocardiographic
ECG 5 electrocardiogram, electrocardiographic
PDS 5 perfusion defect size
SPECT 5 single-photon emission computed tomography (tomographic)
Figure 1. Population screened for study analysis.
Table 1. Reason for Ineligibility in ACIP Trial
No. of
Patients
Qualifying AECG without evidence of ischemia 41
Qualifying coronary angiogram without significant CAD 4
Qualifying exercise test without ST segment depression 1
Patient not suitable for coronary revascularization 2
Patient not willing to participate 4
Personal physician not willing to let patient participate 2
Recent coronary revascularization 1
Other exclusion criteria 1
AECG 5 ambulatory electrocardiogram; CAD 5 coronary artery disease.
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puter generated and normalized using a circumferential profile
analysis that has been previously described in detail (2,26). The
raw data polar maps for each patient were then statistically
compared with an appropriate normal data bank to determine
total left ventricular perfusion defect size (PDS) and extent of
scintigraphic scar and ischemia. Total PDS is the extent of left
ventricular hypoperfusion induced by stress, whereas ischemic
PDS is that component of the total defect which subsequently
improves its perfusion on rest imaging. Myocardial ischemia by
SPECT was defined as the presence of an ischemic perfusion
defect. The intraobserver and interobserver reproducibility of
our method for quantifying perfusion defects is excellent, with
correlation coefficients of 0.98 and 0.97, respectively (38). A
perfusion scan was considered abnormal if a perfusion defect
$3% was present.
Statistical analysis. Demographic, clinical and angio-
graphic findings at entry were analyzed for associations with
AECG monitoring and SPECT findings. The sensitivity for
detecting significant ($50% diameter stenosis) coronary artery
disease was based on the presence of a significant ($3%)
perfusion defect (ischemic or nonischemic), as assessed by
SPECT, or $1-mm ST segment depression lasting $1 min, as
assessed by AECG monitoring. The p values were calculated
using chi-square, Mantel Haenszel or Student t tests as appro-
priate. Forward stepwise logistic regression using the SAS (39)
software package was performed to determine variables inde-
pendently associated with abnormalities on AECG or SPECT.
The following variables were considered potential prognostic
factors for abnormalities on SPECT: age, gender, stenosis
severity, exercise duration, presence of ischemia on the exer-
cise ECG and number of ischemic episodes on AECG. The
following variables were considered potential prognostic fac-
tors for abnormalities on AECG: age, gender, stenosis severity,
exercise duration, presence of ischemia on the exercise ECG
and presence of abnormalities on SPECT. Variables entered
and remained in the model if the p value for association with
the outcome variable was#0.05. Linear regression analysis was
used to define associations between total and ischemic PDSs
and number of episodes of AECG ischemia. A priori, a p value
,0.01 was taken to indicate statistical significance for all the
ACIP study analyses.
Results
Coronary angiographic findings. Of the 106 patients who
underwent coronary angiography, 105 had significant ($50%)
coronary artery stenosis. Sixty-eight percent of patients had
multivessel coronary artery disease, and 57% had significant
($50%) proximal stenosis of the left anterior descending (n 5
26), right (n 5 25) or circumflex (n 5 19) coronary artery.
These results are similar to those found in the ACIP random-
ized patients (37). Seventy-five percent of patients had at least
one severe ($70%) coronary stenosis, and 40% of patients had
a totally occluded artery. Forty-three percent of patients had
evidence of a complex atherosclerotic plaque in one or more of
the coronary arteries.
Exercise test results. In the 92 patients who underwent
both exercise treadmill testing and SPECT, the mean exercise
time was 7.4 6 2.4 min, with a mean maximal heart rate of
1346 19 beats/min. The mean maximal systolic blood pressure
at peak exercise was 178 6 26 mm Hg. Seventy-one patients
(77%) had significant ($1 mm) ST segment depression, and
34% developed angina during the exercise test. Of the 71
patients with a treadmill ECG for positive ischemia, 52 had
abnormalities on SPECT, and 50 had AECG ischemia.
Scintigraphic results. The mean quantified total and isch-
emic left ventricular PDSs for the 106 patients studied were
14 6 14% (median 11%) and 8 6 9%, respectively. Seventy-
eight of the 105 patients (74%) with significant ($50%)
coronary artery disease had abnormalities on SPECT. One
patient with insignificant coronary artery disease had normal
scan results. Seventy percent of patients with single-vessel,
66% of those with double-vessel and 88% of patients with
triple-vessel coronary artery disease had abnormalities on
SPECT. Abnormalities on SPECT occurred more frequently in
patients with severe ($70%) versus a lesser degree (,70%) of
coronary artery stenosis (84% vs. 42%, respectively, p ,
0.001). The most important angiographic predictors of abnor-
malities on SPECT were extent of coronary artery disease (p5
0.04) and stenosis severity (p , 0.001). By logistic regression
analysis, stenosis severity was the most important predictor of
scan abnormalities (p 5 0.001), followed by shorter treadmill
exercise time duration (p 5 0.016) and older patient age (p 5
0.04).
Ambulatory electrocardiographic results. Sixty-five pa-
tients (61%) had evidence of AECG ischemia over the 48-h
monitoring period. Seventeen patients had one episode, 13 had
two episodes, 12 had three episodes, 6 had four episodes, and
17 had five or more ischemic episodes. The mean number of
ischemic ST segment episodes/day was 2.7 6 6.8. The one
patient with insignificant coronary artery disease had an
AECG positive for ischemia. Fifty-eight percent of patients
with single-vessel, 63% of patients with double-vessel and 62%
of those with triple-vessel coronary artery disease had AECG
ischemia. A similar percentage of patients with $70% and
,70% stenosis had positive AECG results for ischemia (63%
vs. 58%, respectively, p5NS). Neither plaque morphology nor
extent, location and severity of coronary artery disease pre-
dicted ischemia by AECG monitoring. The only angiographic
predictor of ischemia was proximal coronary artery stenosis
(p 5 0.04). By logistic regression analysis, the only variable
associated with AECG ischemia was the presence of ST
segment depression on the initial exercise treadmill test (p 5
0.021). Seventy percent of patients with exercise-induced ST
segment depression had an AECG positive for ischemia versus
only 43% of patients with an exercise test negative for ischemia
(p 5 0.02).
Relation between AECG ischemia and that detected with
perfusion imaging. Fifty-eight percent of patients with SPECT
abnormalities and 71% of those with normal scan results had
ischemia by AECG. Conversely, 69% and 81% of patients with
either abnormal or normal AECG results had abnormalities on
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SPECT, respectively. As shown in Figure 2, only a 50%
concordance was observed between SPECT and the AECG,
which minimally improved when the presence of scintigraphic
ischemia was compared with that of AECG ischemia. No
relation was observed between the SPECT PDS (total or
ischemic) and the frequency (Fig. 3) or duration of ischemia as
assessed by AECG monitoring.
Discussion
An original finding from this investigation is the weak
correlation observed between the markers of ischemia tradi-
tionally ascribed to AECG monitoring and stress SPECT. A
surprising result was the lack of correlation between the
number and duration of ischemic episodes detected by AECG
and the size of the total or ischemic PDS as quantified by
SPECT. Superficially, this lack of correlation may seem para-
doxic, but it is not entirely unexpected in light of previously
published studies describing what AECG monitoring and
SPECT actually measure. In the present study, as in many
others, abnormalities on SPECT were related to the extent and
severity of coronary artery disease. However, the presence of
ischemia during daily life as detected by the AECG was not
related to either of these angiographic variables. AECG isch-
emia is known to have poor predictive accuracy for detecting
coronary artery disease as defined by angiography. It would
appear that SPECT and AECG monitoring detect different
pathophysiologic processes as defined under the broad term
“myocardial ischemia.” Because both tests have prognostic
value but seem distinctly unrelated, combining these modali-
ties may further describe the functional significance of coro-
nary artery disease as well as enhance risk stratification.
Myocardial perfusion imaging. The SPECT results ob-
served in this relatively small patient series are consistent with
other large published reports (1–5). The overall sensitivity of
74% that we report for detecting significant coronary artery
disease is only slightly lower than the 85% sensitivity previously
published (1). As in other studies (1,2), the extent and severity
of coronary artery disease best predicted an abnormal scan
result. This finding is not surprising because with more exten-
sive coronary artery disease, there is a greater likelihood of
having one severe stenosis leading to abnormal rest coronary
flow reserve and a perfusion defect. However, because of the
diffuse yet patchy distribution of coronary atherosclerosis,
some seemingly only moderate (50% to 70%) stenoses may
cause severe relative flow limitations, whereas many others of
similar angiographic severity may induce minor regional dif-
ferences and remain undetected. This finding was clearly
observed in the present study: Although the majority (84%) of
patients with severe coronary stenoses were detected, only
42% of patients with moderate stenoses had SPECT abnor-
malities. The slightly lower overall sensitivity of SPECT in the
present study (74%) may be attributable to the relatively large
percentage of patients (25%) with only moderate coronary
artery stenosis by angiography, where perfusion defects are less
predictably induced than in patients with severe stenosis (40).
Our quantitative SPECT results are consistent with previ-
ous reports. The mean PDS for our study cohort was 146 14%
(range 0% to 57%), which is virtually identical to the 14% PDS
reported previously from our group in patients referred for
chest pain evaluation (2). The wide range of myocardial
perfusion defects observed in the present study (0% to 57%) is
typical for patients with coronary artery disease and should
Figure 2. Comparison of SPECT and AECG results when an abnor-
mal SPECT result was defined as 1) any significant ($3%) perfusion
defect (A), or 2) requiring the presence of an ischemic defect (B). 2 5
normal test result; 1 5 abnormal test result.
Figure 3. Scatterplots comparing the number of episodes of AECG
ischemia with the total (top) and ischemic (bottom) perfusion defect
size as quantified by SPECT. Linear regression analysis showed a poor
correlation between SPECT and AECG ischemia variables (r 5
20.018 and r 5 0.035, respectively). LV 5 left ventricle.
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have enhanced our ability to detect a relation between AECG
variables of ischemia and those observed with SPECT.
Ambulatory electrocardiographic monitoring. The pres-
ence of AECG ischemia during daily life has clearly been
associated with both severe (death or myocardial infarction)
and less severe (revascularization, hospital admission, worsen-
ing angina) cardiac events among patients presenting with a
broad spectrum of symptomatic and asymptomatic coronary
artery disease (28,30–31,41–42). However, the pathophysio-
logic mechanisms responsible for asymptomatic AECG isch-
emia are incompletely understood. Among patients with cor-
onary artery disease, ST segment depression during exercise
testing, particularly at a low heart rate, is generally acknowl-
edged to enhance the probability of detecting AECG ischemia.
Depending on the type of patient studied, ;25% to 50% of
those with ST segment depression during exercise will have
AECG ischemia. The probability of having AECG ischemia
increases when there is prolonged ST depression after exercise
and when ST depression occurs at low exercise work loads
(42,43). An increase in heart rate usually precedes AECG
ischemia (44).
The extent and severity of angiographic coronary artery
disease is a highly variable predictor of ischemia as assessed by
AECG monitoring (45–48), suggesting that coronary stenoses
as subjectively defined by coronary angiography are only in
part a predictor of ischemia during daily life. Other processes
that contribute to the functional and prognostic significance of
coronary artery disease are dynamic changes in coronary size
at the epicardial, microvascular or collateral level as well as
platelet microaggregates and thrombus formation. These pro-
cesses would not necessarily be evident using “lumenology”
derived from coronary angiography but could contribute to the
development of ischemia during daily life. The poor associa-
tion between coronary angiographic findings and ischemia by
AEG would be particularly true if coronary endothelial dys-
function contributed to a reduction in coronary blood flow
during psychological and environmental stressors present in
daily life. Such stressors may not be operative with SPECT
imaging. Thus, although AECG and SPECT both measure
myocardial ischemia, the reduction in coronary blood flow
detected by these techniques appears to occur by means of
different mechanisms.
Study limitations. The present study was a retrospective
analysis of patients evaluated for enrollment in the ACIP study
who had known coronary artery disease and were at high risk
because of the presence of exercise and AECG ischemia. In
this regard, our study limited its analyses predominantly to
those patients with substantial myocardial ischemia. However,
this cohort would seem to be a relevant patient group to study
when investigating whether two diagnostic tests detect isch-
emia in a similar manner. Another limitation is that the AECG
and SPECT studies were not performed at the same time or
under identical conditions. Many patients during SPECT im-
aging were still taking anti-ischemic medications, which are
known to influence the total PDS (49), whereas most AECG
monitoring was performed without anti-ischemic drugs, as part
of the ACIP protocol. Anti-ischemic drug therapy may have
reduced the SPECT PDS in many patients and led to a normal
scan result in others, thus underestimating the sensitivity of
SPECT. Finally, although the sample size was relatively small
and limited to mostly men, this is the largest cohort to be
studied with both techniques to date.
Clinical implications. This study demonstrates a lack of
correlation between daily life myocardial ischemia variables as
detected by AECG monitoring compared with traditional
coronary angiographic variables or the presence and extent of
myocardial hypoperfusion as quantified by SPECT. This dis-
cordance supports the hypothesis that the presence of AECG
ischemia is more dependent on altered coronary vasomotion or
plaque instability. The possibility that different, but clinically
important, components of risk for ischemia-related adverse
outcomes are measured by SPECT and AECG suggests that
the results of the two tests may be complementary in more fully
defining which patients with coronary artery disease are at
highest risk for subsequent cardiac events.
References
1. Mahmarian JJ, Verani MS. Exercise thallium-201 perfusion scintigraphy in
the assessment of coronary artery disease. Am J Cardiol 1991;67:2D–11D.
2. Mahmarian JJ, Boyce TM, Goldberg RK, Cocanougher MK, Roberts R,
Verani MS. Quantitative exercise thallium-201 single-photon emission com-
puted tomography for the enhanced diagnosis of ischemic heart disease.
J Am Coll Cardiol 1990;15:318–29.
3. DePasquale EE, Nody AC, DePuey EG, et al. Quantitative rotational
thallium-201 tomography for identifying and localizing coronary artery
disease. Circulation 1988;77:316–27.
4. Iskandrian AS, Heo J, Kong B, Lyons E. Effect of exercise level on the ability
of thallium-201 tomographic imaging in detecting coronary artery disease:
analysis of 461 patients. J Am Coll Cardiol 1989;14:1477–86.
5. Maddahi J, Van Train K, Prigent F, et al. Quantitative single photon
emission computed thallium-201 tomography for detection and localization
of coronary artery disease: optimization and prospective validation of a new
technique. J Am Coll Cardiol 1989;14:1689–99.
6. Francisco DA, Collins SM, Go RT, Ehrhardt JC, VanKirk OC, Marcus ML.
Tomographic thallium-201 myocardial perfusion scintigrams after maximal
coronary artery vasodilation with intravenous dipyridamole: comparison of
qualitative and quantitative approaches. Circulation 1982;66:370–9.
7. Leppo J, Boucher CA, Okada RD, Newell JB, Strauss HW, Pohost GM.
Serial thallium-201 myocardial imaging after dipyridamole infusion: diagnos-
tic utility in detecting coronary stenoses and relationship to regional wall
motion. Circulation 1982;66:649–57.
8. Mendelson MA, Spies SM, Spies WG, Abi-Mansour P, Fintel DJ. Usefulness
of single-photon emission computed tomography of thallium-201 uptake
after dipyridamole infusion for detection of coronary artery disease. Am J
Cardiol 1992;69:1150–5.
9. Iskandrian AS, Heo J, Nguyen T, et al. Assessment of coronary artery
disease using single-photon emission computed tomography with thallium-
201 during adenosine-induced coronary hyperemia. Am J Cardiol 1991;67:
1190–4.
10. Nishimura S, Mahmarian JJ, Boyce TM, Verani MS. Quantitative thallium-
201 single-photon emission computed tomography during maximal pharma-
cologic coronary vasodilation with adenosine for assessing coronary artery
disease. J Am Coll Cardiol 1991;18:736–45.
11. Pennell DJ, Underwood SR, Swanton RH, Walker JM, Ell PJ. Dobutamine
thallium myocardial perfusion tomography. J Am Coll Cardiol 1991;18:
1471–9.
12. Hays JT, Mahmarian JJ, Cochran AJ, Verani MS. Dobutamine thallium-201
tomography for evaluating patients with suspected coronary artery disease
unable to undergo exercise or vasodilator pharmacologic stress testing. J Am
Coll Cardiol 1993;21:1583–90.
768 MAHMARIAN ET AL. JACC Vol. 29, No. 4
AMBULATORY ECG AND MYOCARDIAL PERFUSION IMAGING March 15, 1997:764–9
13. Wackers FJ, Russo DJ, Russo D, Clements JP. Prognostic significance of
normal quantitative planar thallium-201 stress scintigraphy in patients with
chest pain. J Am Coll Cardiol 1985;6:27–30.
14. Ladenheim ML, Pollock BH, Rozanski A, et al. Extent and severity of
myocardial hypoperfusion as predictors of prognosis in patients with sus-
pected coronary artery disease. J Am Coll Cardiol 1986;7:464–71.
15. Kaul S, Finkelstein DM, Homma S, Leavitt M, Okada RD, Boucher CA.
Superiority of quantitative exercise thallium-201 variables in determining
long-term prognosis in ambulatory patients with chest pain: a comparison
with cardiac catheterization. J Am Coll Cardiol 1988;12:25–34.
16. Iskandrian AS, Hakki AH, Kane-Marsch S. Prognostic implications of
exercise thallium-201 scintigraphy in patients with suspected or known
coronary artery disease. Am Heart J 1985;110:135–43.
17. Gill JB, Ruddy TD, Newell JB, Finkelstein DM, Strauss HW, Boucher CA.
Prognostic importance of thallium uptake by the lungs during exercise in
coronary artery disease. N Engl J Med 1987;317:1486–89.
18. Mahmarian JJ, Verani MS. Myocardial perfusion imaging during pharma-
cologic stress testing. Cardiol Clin 1994;12:223–45.
19. Hendel RC, Layden JJ, Leppo JA. Prognostic value of dipyridamole thallium
scintigraphy for evaluation of ischemic heart disease. J Am Coll Cardiol
1990;15:109–16.
20. Shaw L, Chaitman BR, Hilton TC, et al. Prognostic value of dipyridamole
thallium-201 imaging in elderly patients. J Am Coll Cardiol 1992;19:1390–8.
21. Iskandrian AS, Chae SC, Heo J, Stanberry CD, Wasserleben V, Cave V.
Independent and incremental prognostic value of exercise single-photon
emission computed tomographic (SPECT) thallium imaging in coronary
artery disease. J Am Coll Cardiol 1993;22:665–70.
22. Marie PY, Danchin N, Durand JF, et al. Long-term prediction of major
ischemic events by exercise thallium-201 single-photon emission computed
tomography: incremental prognostic value compared with clinical, exercise
testing, catheterization and radionuclide angiographic data. J Am Coll
Cardiol 1995;26:879–86.
23. Gibson RS, Watson DD, Craddock GB, et al. Prediction of cardiac events
after uncomplicated myocardial infarction: a prospective study comparing
predischarge exercise thallium-201 scintigraphy and coronary angiography.
Circulation 1983;68:321–36.
24. Brown KA, O’Meara J, Chambers CE, Plante DA. Ability of dipyridamole-
thallium-201 imaging one to four days after acute myocardial infarction to
predict in-hospital and late recurrent myocardial ischemic events. Am J
Cardiol 1990;65:160–7.
25. Leppo JA, O’Brien J, Rothendler JA, Getchell JD, Lee VW. Dipyridamole-
thallium-201 scintigraphy in the prediction of future cardiac events after
acute myocardial infarction. N Engl J Med 1984;310:1014–8.
26. Mahmarian JJ, Mahmarian AC, Marks GF, Pratt CM, Verani MS. Role of
adenosine thallium-201 tomography for defining long-term risk in patients
after acute myocardial infarction. J Am Coll Cardiol 1995;25:1333–40.
27. Rocco MB, Nabel EG, Campbell S, et al. Prognostic importance of
myocardial ischemia detected by ambulatory monitoring in patients with
stable coronary artery disease. Circulation 1988;78:877–84.
28. Deedwania PC, Carbajal EV. Silent ischemia during daily life is an indepen-
dent predictor of mortality in stable angina. Circulation 1990;81:748–56.
29. Gottlieb SO, Gottlieb SH, Achuff SC, et al. Silent ischemia on Holter
monitoring predicts mortality in high-risk postinfarction patients. JAMA
1988;259:1030–5.
30. Gottlieb SO, Weisfeldt ML, Ouyang P, Mellits ED, Gerstenblith G. Silent
ischemia as a marker for early unfavorable outcomes in patients with
unstable angina. N Engl J Med 1986;314:1214–9.
31. Gill JB, Cairns JA, Roberts RS, et al. Prognostic importance of myocardial
ischemia detected by ambulatory monitoring early after acute myocardial
infarction. N Engl J Med 1996;334:65–70.
32. Pepine CJ, Cohn PF, Deedwania PC, et al. Effects of treatment on outcome
in mildly symptomatic patients with ischemia during daily life: the Atenolol
Silent Ischemia Study (ASIST). Circulation 1994;90:762–8.
33. Schang SJ Jr, Pepine CJ. Transient asymptomatic S-T segment depression
during daily activity. Am J Cardiol 1977;39:396–402.
34. Campbell S, Barry J, Rebecca GS, et al. Active transient myocardial ischemia
during daily life in asymptomatic patients with positive exercise tests and
coronary artery disease. Am J Cardiol 1986;57:1010–6.
35. Imperi GA, Lambert CR, Coy K, Lopez L, Pepine CJ, Shephard C. Effects
of titrated beta blockade (metoprolol) on silent myocardial ischemia in
ambulatory patients with coronary artery disease. Am J Cardiol 1987;60:
519–24.
36. Stone PH, Gibson RS, Glasser SP, et al. Comparison of propranolol,
diltiazem, and nifedipine in the treatment of ambulatory ischemia in patients
with stable angina. Differential effects on ambulatory ischemia, exercise
performance, and anginal symptoms: the ASIS Study Group. Circulation
1990;82:1962–72.
37. Pepine CJ, Geller NL, Knatterud GL, et al. The Asymptomatic Cardiac
Ischemia Pilot (ACIP) study: design of a randomized clinical trial, baseline
data and implications for a long-term outcome trial. J Am Coll Cardiol
1994;24:1–10.
38. Mahmarian JJ, Pratt CM, Cocanougher MK, Verani MS. Altered myocardial
perfusion in patients with angina pectoris or silent ischemia during exercise
as assessed by quantitative thallium-201 single-photon emission computed
tomography. Circulation 1990;82:1305–15.
39. SAS/STAT Users Guide Version 6, vol. 2. 4th ed. SAS Institute Inc.,
1993:1071–126.
40. Miller DD, Donohue TJ, Younis LT, et al. Correlation of pharmacological
Tc-99m-sestamibi myocardial perfusion imaging with poststenotic coronary
flow reserve in patients with angiographically intermediate coronary artery
stenoses. Circulation 1994;89:2150–60.
41. Tzivoni D, Gavish A, Zin D, et al. Prognostic significance of ischemic
episodes in patients with previous myocardial infarction. Am J Cardiol
1988;62:661–4.
42. Mody FV, Nademanee K, Intarachot V, Josephson MA, Robertson HA,
Singh BN. Severity of silent myocardial ischemia on ambulatory electrocar-
diographic monitoring in patients with stable angina pectoris: relation to
prognostic determinants during exercise stress testing and coronary angiog-
raphy. J Am Coll Cardiol 1988;12:1169–76.
43. Campbell S, Barry J, Rocco MB, et al. Features of the exercise test that
reflect the activity of ischemic heart disease out of hospital. Circulation
1986;74:72–80.
44. Deedwania PC, Carbajal EV. Silent myocardial ischemia: prognosis and
treatment recommendations. Prim Cardiol 1991;17:37–50.
45. Yeung AC, Barry J, Orav J, Bonassin E, Raby KE, Selwyn AP. Effects of
asymptomatic ischemia on long-term prognosis in chronic stable coronary
disease. Circulation 1991;83:1598–604.
46. Kunkes SH, Pichard AD, Smith H Jr, Gorlin R, Herman MV, Kupersmith J.
Silent ST segment deviations and extent of coronary artery disease.
Am Heart J 1980;100:813–20.
47. Von Arnim T, Gerbig HW, Krawietz W, Hofling B. Prognostic implications
of transient—predominantly silent—ischaemia in patients with unstable
angina pectoris. Eur Heart J 1988;9:435–40.
48. Langer A, Freeman MR, Armstrong PW. ST segment shift in unstable
angina: pathophysiology and association with coronary anatomy and hospital
outcome. J Am Coll Cardiol 1989;13:1495–502.
49. Mahmarian JJ, Fenimore NL, Marks GF, et al. Transdermal nitroglycerin
patch therapy reduces the extent of exercise-induced myocardial ischemia:
results of a double-blind, placebo-controlled trial using quantitative
thallium-201 tomography. J Am Coll Cardiol 1994;24:25–32.
769JACC Vol. 29, No. 4 MAHMARIAN ET AL.
March 15, 1997:764–9 AMBULATORY ECG AND MYOCARDIAL PERFUSION IMAGING
